December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novavax, Inc. - Common Stock (NQ:NVAX)

8.890 +0.270 (+3.13%)
Official Closing Price Updated: 4:15 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novavax, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Trump Administration Terminates $590 Million Moderna Bird Flu Vaccine Deal, Dismantling Biden-Era Pandemic Preparedness Effort
The Trump administration terminated a nearly $600 million award to Moderna for developing an mRNA-based bird flu vaccine, ending a key Biden-era pandemic preparedness initiative. The cancellation... 
Via Benzinga
Topics Government
Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For 'Healthy' Pregnant Women, Children
RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed. 
Via Benzinga
Analysts Think These Stocks Could More Than Double in Value
Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well. 
Via MarketBeat
Topics World Trade
What's Driving the Market Sentiment Around Novavax?
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Uncovering Potential: Novavax's Earnings Preview
 
Via Benzinga
FDA Limits Annual COVID-19 Boosters To High-Risk Americans, Demands New Trials For Healthy Adults In Policy Shift Under RFK Jr.
The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter... 
Via Benzinga
FDA Sets New Guidelines For Approving COVID-19 Booster Shots In Healthy Individuals: Moderna, Novavax Stocks Rise
The agency plans to demand stronger evidence of efficacy for the shots before approval is granted for healthy persons, between the ages of six months and 64 years, with no risk factors for severe... 
Via Stocktwits
The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped.
The new framework limits future Covid shots to people age 65 and older and those six months and older with a risk factor for serious illness. 
Via Investor's Business Daily
Topics Bankruptcy Government
US Stocks Likely To Open Lower After S&P 500's Six-Day Streak: 'Quick Recoveries Tend To See Stocks Rally More Over The Next 3-12 Months,' Says Expert
U.S. stock futures were slightly lower on Tuesday after ending largely flat on Monday. Futures of major benchmark indices were trading lower in premarket. 
Via Benzinga
Topics Stocks
Dow Surges Over 100 Points Despite Moody's US Downgrade: Fear Index Remains In 'Greed' Zone
 
Via Benzinga
Topics Stocks
Stocks Mixed, Treasury Bonds Slip On Moody's US Downgrade: What's Driving Markets Monday?
U.S. stocks trimmed early-session losses by midday Monday, as investors showed limited concern after Moody's downgraded U.S. sovereign credit from Aaa to Aa1, effectively stripping the world's largest... 
Via Benzinga
Topics Economy
Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall. 
Via Benzinga
Gapping stocks in Monday's session
Let's have a look at what is happening on the US markets on Monday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
CI&T, Novavax, Paramount Group And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Novavax Stock Rips Nearly 20% Pre-Market After FDA Approves Its COVID-19 Vaccine Nuvaxovid
Novavax CEO John C. Jacobs called the approval a “significant milestone” as the company seeks to make its protein-based COVID-19 vaccine commercially available. 
Via Stocktwits
Topics Government Stocks
These stocks are moving in today's pre-market session
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
US Stocks Likely To Open Lower After Moody's Downgrade: 'Bear Market Isn't Fully Recovered Yet, But It Is Close,' Says Expert
U.S. stock futures dipped on Monday after closing higher for the day and the week on Friday. Futures were trading lower in premarket. 
Via Benzinga
Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions... 
Via Benzinga
Novavax Wins FDA Approval For COVID-19 Vaccine: Retail Calls For Buyback And Bigger Moves
The pharma company secured FDA clearance to manufacture and distribute its COVID-19 vaccine Nuvaxovid for adults and at-risk groups, with no advisory committee hurdles. 
Via Stocktwits
Benzinga Bulls And Bears: IBM, Novavax, Arm Holdings — And UK Trade Deal Boosts Markets
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why
Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year outlook raised above expectations. 
Via Benzinga
Thursday's Top 5 Trending Stocks: What's Going On With D-Wave, Novavax, Carvana?
D-Wave Quantum Inc. (NYSE:QBTS), Asset Entities, Inc. (NASDAQ:ASST), Alphabet, Inc. 
Via Benzinga
Novavax Stock Rallies On Upbeat Q1 Earnings, Revised Full-Year Revenue Forecast: Retail’s Elated
The company raised its full-year revenue guidance to between $975 million and $1.025 billion, up from its previous guidance of between $300 million and $350 million. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.